ENBIOTIX
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
ENBIOTIX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.enbiotix.com
Total Employee:
1+
Status:
Active
Contact:
5084001856
Email Addresses:
[email protected]
Total Funding:
17.61 M USD
Technology used in webpage:
SPF Domain Not Resolving Euro Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS AJAX Libraries API GoDaddy DNS AWS Global Accelerator
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Curex Allergy
Curex offers at-home allergy testing, online doctor consultations and allergy treatment services.
Generian Pharmaceuticals
Generian has developed an innovative approach to uncover first-in-class, gain-of-function drugs that activate key cellular networks.
Labviva
Labviva is a digital marketplace for life science products that connects researchers with suppliers.
QSimulate
QSimulate is leveraging the power of quantum mechanics to solve industrial-scale problems like never before.
Resource Label Group
Resource Label Group is a prime label and narrow web film converter with facilities.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
United Allergy Services
United Allergy Services knows that every patient is different. Each responds differently to different allergens. That’s why they
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-11-03 | AMP Therapeutics - Antimicrobial Peptides | AMP Therapeutics - Antimicrobial Peptides acquired by EnBiotix | N/A |
Investors List
Vectura Group
Vectura Group investment in Convertible Note - EnBiotix
Sanford Biosciences
Sanford Biosciences investment in Convertible Note - EnBiotix
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Convertible Note - EnBiotix
Apeiron Holdings Limited
Apeiron Holdings Limited investment in Series A - EnBiotix
Wired Holdings
Wired Holdings investment in Series A - EnBiotix
Official Site Inspections
http://www.enbiotix.com Semrush global rank: 5.13 M Semrush visits lastest month: 729
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "EnBiotix"
EnBiotix, Inc. - Devex
EnBiotix is a late clinical-stage respiratory therapeutics company initially advancing front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections, a $15 billion …See details»
About Spexis – Spexis
Spexis was created in December 2021 through the merger of EnBiotix, Inc., a privately held US biotech, into Polyphor AG, a publicly listed Swiss biotechnology company. EnBiotix was granted four of the six board seats and EnBiotix …See details»
EnBiotix Company Profile 2024: Valuation, Investors, Acquisition ...
EnBiotix General Information Description. Operator of a bioengineering company specializing in the development of therapies for drug-resistant bacterial infections. The company develops …See details»
EnBiotix - Org Chart, Teams, Culture & Jobs - The Org
EnBiotix is a late clinical-stage rare disease company currently focused on therapies for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections, a $15 billion …See details»
EnBiotix - Funding, Financials, Valuation & Investors - Crunchbase
EnBiotix has acquired AMP Therapeutics - Antimicrobial Peptides on Nov 3, 2016. Unlock for free . Funding Rounds. Edit Funding Rounds Section. ... How much funding has this organization …See details»
Polyphor Closes Merger with EnBiotix and is Renamed Spexis
Dec 30, 2021 Pursuant to completion of the capital increase approved at the extraordinary general meeting of shareholders convened on October 28, 2021, Polyphor and EnBiotix, a …See details»
EnBiotix, Inc. Closes $11M Pre-Merger Financing - GlobeNewswire
Dec 29, 2021 EnBiotix is a late-clinical stage rare disease company with an initial focus on chronic respiratory disorders, an estimated $15 billion global market with millions of patients …See details»
Spexis acquires EnBiotix - 2021-09-01 - Crunchbase
Acquired Organization: EnBiotix EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Acquiring Organization: Spexis Spexis is …See details»
EnBiotix, Inc. Closes $11M Pre-Merger Financing
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M …See details»
Polyphor AG and EnBiotix Inc. Joint Meeting - Spexis
EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases Polyphor and EnBiotix have signed a merger …See details»
EnBiotix and Elanco Enter Partnership to Develop ... - SynBioBeta
EnBiotix will be bringing its intellectual property surrounding phage engineering to the partnership, while Elanco will bring funding and resources. Per the agreement, Elanco will have the right to …See details»
Startups on the Menu: EnBiotix | Nature Biotechnology
Mar 21, 2013 Nature Biotechnology: Describe the process for how EnBiotix came together. Jim Collins: Jeff Wager and I met in the fall of 2011, via BU's Office of Technology Development. …See details»
Polyphor and EnBiotix Announce Signing of Merger Agreement …
Sep 1, 2021 Polyphor and EnBiotix have signed a merger agreement. EnBiotix acquires Inhaled Murepavadin at an agreed valuation of USD 10 million in exchange for 2'599'655 of common …See details»
Polyphor and EnBiotix Announce Signing of Merger Agreement …
Sep 1, 2021 EnBiotix acquires Inhaled Murepavadin at an agreed valuation of USD 10 million in exchange for 2'599'655 of common shares of EnBiotix (15.4% fully diluted of EnBiotix). ...See details»
EnBiotix Closes $11 Million Financing Ahead of Merger with …
Dec 29, 2021 EnBiotix expects to move ColiFin into phase 3 clinical trials in 2022. Proceeds will also help fund EnBiotix’s obligations related to its ongoing phase 1 study of inhaled …See details»
EnBiotix, Inc. Closes $11M Pre-Merger Financing - Yahoo Finance
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M …See details»
EnBiotix Raises $11M to Develop Antibiotics for Lung Infections
Dec 30, 2021 EnBiotix acquired murepavadin as part of its merger agreement with Polyphor. EnBiotix and Polyphor recently announced the launch of a Phase 1 clinical trial that is testing …See details»
EnBiotix | Bill & Melinda Gates Foundation
EnBiotix Committed grants. More in this section Committed grants. EnBiotix Grantee website Cambridge, Massachusetts, United States Purpose. to identify new treatments for enteric …See details»